Biofluid Detection of Pathological α-Synuclein in the Prodromal Phase of Synucleinopathies.

IF 4 3区 医学 Q2 NEUROSCIENCES Journal of Parkinson's disease Pub Date : 2024-01-01 DOI:10.3233/JPD-230429
Annika Kluge, Alex Iranzo
{"title":"Biofluid Detection of Pathological α-Synuclein in the Prodromal Phase of Synucleinopathies.","authors":"Annika Kluge, Alex Iranzo","doi":"10.3233/JPD-230429","DOIUrl":null,"url":null,"abstract":"<p><p>Synucleinopathies are disorders characterized by the aggregation and deposition of pathological α-synuclein conformers. The underlying neurodegenerative processes begin years or decades before the onset of cardinal motor symptoms. This prodromal phase may manifest with various signs or symptoms. However, there are no current standardized laboratory tests to ascertain the progression and conversion of prodromal conditions such as mild cognitive impairment, isolated REM sleep behavior disorder or pure autonomic failure. The aim of this systematic review was to evaluate the diagnostic possibilities using human biofluids as source material to detect pathological α-synuclein in the prodromal phase of synucleinopathies. Our review identified eight eligible studies, that investigated pathological α-synuclein conformers using cerebrospinal fluid from patients with prodromal signs of synulceinopathies to differentiate this patient group from non-synucleinopathies, while only one study investigated this aspect using blood as medium. While previous studies clearly demonstrated a high diagnostic performance of α-synuclein seed amplification assays for differentiating synucleinopathies with Lewy bodies from healthy controls, only few analyses were performed focussing on individuals with prodromal disease. Nevertheless, results for the early detection of α-synuclein seeds using α-synuclein seed amplification assays were promising and may be of particular relevance for future clinical trials and clinical practice.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"S323-S331"},"PeriodicalIF":4.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11494638/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Parkinson's disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/JPD-230429","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Synucleinopathies are disorders characterized by the aggregation and deposition of pathological α-synuclein conformers. The underlying neurodegenerative processes begin years or decades before the onset of cardinal motor symptoms. This prodromal phase may manifest with various signs or symptoms. However, there are no current standardized laboratory tests to ascertain the progression and conversion of prodromal conditions such as mild cognitive impairment, isolated REM sleep behavior disorder or pure autonomic failure. The aim of this systematic review was to evaluate the diagnostic possibilities using human biofluids as source material to detect pathological α-synuclein in the prodromal phase of synucleinopathies. Our review identified eight eligible studies, that investigated pathological α-synuclein conformers using cerebrospinal fluid from patients with prodromal signs of synulceinopathies to differentiate this patient group from non-synucleinopathies, while only one study investigated this aspect using blood as medium. While previous studies clearly demonstrated a high diagnostic performance of α-synuclein seed amplification assays for differentiating synucleinopathies with Lewy bodies from healthy controls, only few analyses were performed focussing on individuals with prodromal disease. Nevertheless, results for the early detection of α-synuclein seeds using α-synuclein seed amplification assays were promising and may be of particular relevance for future clinical trials and clinical practice.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
突触核蛋白病前驱期病理α-突触核蛋白的生物流体检测
突触核蛋白病是一种以病理性α-突触核蛋白构象物的聚集和沉积为特征的疾病。潜在的神经退行性过程始于主要运动症状出现前数年或数十年。前驱期可表现为各种体征或症状。然而,目前还没有标准化的实验室检测方法来确定轻度认知障碍、孤立的快速眼动睡眠行为障碍或纯粹的自主神经功能衰竭等前驱症状的进展和转换。本系统性综述旨在评估以人体生物流体为源材料检测突触核蛋白病前驱期病理α-突触核蛋白的诊断可能性。我们的综述确定了八项符合条件的研究,这些研究使用突触核蛋白病前驱症状患者的脑脊液调查病理α-突触核蛋白构象,以区分该患者群体与非突触核蛋白病,而只有一项研究使用血液作为介质调查这方面的情况。以往的研究清楚地表明,α-突触核蛋白种子扩增测定在区分路易体突触核蛋白病和健康对照组方面具有很高的诊断性能,但针对前驱症状患者的分析却寥寥无几。尽管如此,使用α-突触核蛋白种子扩增检测法早期检测α-突触核蛋白种子的结果还是很有希望的,这可能对未来的临床试验和临床实践具有特别重要的意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.40
自引率
5.80%
发文量
338
审稿时长
>12 weeks
期刊介绍: The Journal of Parkinson''s Disease (JPD) publishes original research in basic science, translational research and clinical medicine in Parkinson’s disease in cooperation with the Journal of Alzheimer''s Disease. It features a first class Editorial Board and provides rigorous peer review and rapid online publication.
期刊最新文献
Prospective Study of Lung Function with Prodromal, Clinical Parkinson's Disease, and Mortality. Winding Back the Clock on Advanced Therapies: It's Time to Get Smart. Non-Pharmacological Interventions for People with Parkinson's Disease: Are We Entering a New Era? Prospective Role of PAK6 and 14-3-3γ as Biomarkers for Parkinson’s Disease U.S. Tax Credits to Promote Practical Proactive Preventative Care for Parkinson’s Disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1